Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma

Patrizia Giannatempo; Alessandra Alessi; Rosalba Miceli; Daniele Raggi; Elena Farè; Nicola Nicolai; Gianluca Serafini; Barbara Padovano; Luigi Piva; Davide Biasoni; Tullio Torelli; Mario Catanzaro; Silvia Stagni; Massimo Maffezzini; Luigi Mariani; Alessandro M. Gianni; Guru Sonpavde; Roberto Salvioni; Andrea Necchi; Flavio Crippa

doi:10.1016/j.clgc.2014.03.007

Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma

Patrizia Giannatempo, Alessandra Alessi, Rosalba Miceli, Daniele Raggi, Elena Farè, Nicola Nicolai, Gianluca Serafini, Barbara Padovano, Luigi Piva, Davide Biasoni, Tullio Torelli, Mario Catanzaro, Silvia Stagni, Massimo Maffezzini, Luigi Mariani, Alessandro M. Gianni, Guru Sonpavde, Roberto Salvioni, Andrea Necchi, Flavio Crippa

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Fluorine-18 fluorodeoxyglucose positron emission tomography is increasingly used by many centers for staging and response assessment of metastatic transitional cell carcinoma. We prospectively evaluated 31 patients undergoing metabolic restaging after only 2 cycles of first-line chemotherapy (PET2). Early metabolic response was associated with patient outcome. The aim was to provide a proof of principle for a risk-adapted approach based on PET2 that may guide new trial design for early-recognized unresponsive patients.

Original language	English
Pages (from-to)	433-439
Number of pages	7
Journal	Clinical Genitourinary Cancer
Volume	12
Issue number	6
DOIs	https://doi.org/10.1016/j.clgc.2014.03.007
Publication status	Published - 2014

Keywords

Imaging biomarkers
Metabolic response
Positron emission tomography
Transitional cell carcinoma
Urothelial cancer

ASJC Scopus subject areas

Oncology
Urology
Medicine(all)

Access to Document

10.1016/j.clgc.2014.03.007

Fingerprint Dive into the research topics of 'Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma'. Together they form a unique fingerprint.

Cite this

Giannatempo, P., Alessi, A., Miceli, R., Raggi, D., Farè, E., Nicolai, N., Serafini, G., Padovano, B., Piva, L., Biasoni, D., Torelli, T., Catanzaro, M., Stagni, S., Maffezzini, M., Mariani, L., Gianni, A. M., Sonpavde, G., Salvioni, R., Necchi, A., & Crippa, F. (2014). Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. Clinical Genitourinary Cancer, 12(6), 433-439. https://doi.org/10.1016/j.clgc.2014.03.007

Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. / Giannatempo, Patrizia ; Alessi, Alessandra ; Miceli, Rosalba; Raggi, Daniele; Farè, Elena; Nicolai, Nicola; Serafini, Gianluca; Padovano, Barbara; Piva, Luigi; Biasoni, Davide ; Torelli, Tullio ; Catanzaro, Mario ; Stagni, Silvia; Maffezzini, Massimo; Mariani, Luigi; Gianni, Alessandro M.; Sonpavde, Guru; Salvioni, Roberto; Necchi, Andrea; Crippa, Flavio.

In: Clinical Genitourinary Cancer, Vol. 12, No. 6, 2014, p. 433-439.

Research output: Contribution to journal › Article › peer-review

Giannatempo, P , Alessi, A , Miceli, R, Raggi, D, Farè, E, Nicolai, N, Serafini, G, Padovano, B, Piva, L, Biasoni, D , Torelli, T , Catanzaro, M , Stagni, S, Maffezzini, M, Mariani, L, Gianni, AM, Sonpavde, G, Salvioni, R, Necchi, A & Crippa, F 2014, 'Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma', Clinical Genitourinary Cancer, vol. 12, no. 6, pp. 433-439. https://doi.org/10.1016/j.clgc.2014.03.007

Giannatempo, Patrizia ; Alessi, Alessandra ; Miceli, Rosalba ; Raggi, Daniele ; Farè, Elena ; Nicolai, Nicola ; Serafini, Gianluca ; Padovano, Barbara ; Piva, Luigi ; Biasoni, Davide ; Torelli, Tullio ; Catanzaro, Mario ; Stagni, Silvia ; Maffezzini, Massimo ; Mariani, Luigi ; Gianni, Alessandro M. ; Sonpavde, Guru ; Salvioni, Roberto ; Necchi, Andrea ; Crippa, Flavio. / Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. In: Clinical Genitourinary Cancer. 2014 ; Vol. 12, No. 6. pp. 433-439.

@article{868ba0145ff84e0794fec96eef012771,

title = "Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma",

abstract = "Fluorine-18 fluorodeoxyglucose positron emission tomography is increasingly used by many centers for staging and response assessment of metastatic transitional cell carcinoma. We prospectively evaluated 31 patients undergoing metabolic restaging after only 2 cycles of first-line chemotherapy (PET2). Early metabolic response was associated with patient outcome. The aim was to provide a proof of principle for a risk-adapted approach based on PET2 that may guide new trial design for early-recognized unresponsive patients.",

keywords = "Imaging biomarkers, Metabolic response, Positron emission tomography, Transitional cell carcinoma, Urothelial cancer",

author = "Patrizia Giannatempo and Alessandra Alessi and Rosalba Miceli and Daniele Raggi and Elena Far{\`e} and Nicola Nicolai and Gianluca Serafini and Barbara Padovano and Luigi Piva and Davide Biasoni and Tullio Torelli and Mario Catanzaro and Silvia Stagni and Massimo Maffezzini and Luigi Mariani and Gianni, {Alessandro M.} and Guru Sonpavde and Roberto Salvioni and Andrea Necchi and Flavio Crippa",

year = "2014",

doi = "10.1016/j.clgc.2014.03.007",

language = "English",

volume = "12",

pages = "433--439",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma

AU - Giannatempo, Patrizia

AU - Alessi, Alessandra

AU - Miceli, Rosalba

AU - Raggi, Daniele

AU - Farè, Elena

AU - Nicolai, Nicola

AU - Serafini, Gianluca

AU - Padovano, Barbara

AU - Piva, Luigi

AU - Biasoni, Davide

AU - Torelli, Tullio

AU - Catanzaro, Mario

AU - Stagni, Silvia

AU - Maffezzini, Massimo

AU - Mariani, Luigi

AU - Gianni, Alessandro M.

AU - Sonpavde, Guru

AU - Salvioni, Roberto

AU - Necchi, Andrea

AU - Crippa, Flavio

PY - 2014

Y1 - 2014

N2 - Fluorine-18 fluorodeoxyglucose positron emission tomography is increasingly used by many centers for staging and response assessment of metastatic transitional cell carcinoma. We prospectively evaluated 31 patients undergoing metabolic restaging after only 2 cycles of first-line chemotherapy (PET2). Early metabolic response was associated with patient outcome. The aim was to provide a proof of principle for a risk-adapted approach based on PET2 that may guide new trial design for early-recognized unresponsive patients.

AB - Fluorine-18 fluorodeoxyglucose positron emission tomography is increasingly used by many centers for staging and response assessment of metastatic transitional cell carcinoma. We prospectively evaluated 31 patients undergoing metabolic restaging after only 2 cycles of first-line chemotherapy (PET2). Early metabolic response was associated with patient outcome. The aim was to provide a proof of principle for a risk-adapted approach based on PET2 that may guide new trial design for early-recognized unresponsive patients.

KW - Imaging biomarkers

KW - Metabolic response

KW - Positron emission tomography

KW - Transitional cell carcinoma

KW - Urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=84922702191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922702191&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2014.03.007

DO - 10.1016/j.clgc.2014.03.007

M3 - Article

C2 - 24787972

AN - SCOPUS:84922702191

VL - 12

SP - 433

EP - 439

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 6

ER -

Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this